The kinase domain of DYRK1A has been the target of specific ATP‐competitive small inhibitors that have been effective in rescuing DS features and improving AD pathology in a murine model (Branca et al., 2017; Kim et al., 2016). This evidence concerns the gene DYRK1A and Dravet syndrome.